17 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 16 Phase 2, 4 Phase 1, 3 Phase 3, 1 Phase 4.
Follow Metastatic Osteosarcoma: new trials by email Literature Review of Metastatic Osteosarcoma trials Research Report on Metastatic Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study Atezolizumab, Cabozantinib - Locally Advanced Osteosarcoma, Metastatic Osteosarcoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2023-04-25 | 2026-10-06 |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Bone Scan, Cabozantinib S-malate, Cisplatin - High Grade Osteosarcoma, Localized Osteosarcoma | Phase 2 / Phase 3 | Suspended | National Cancer Institute (NCI) | 1122 | 2023-03-03 | 2026-10-16 |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Biospecimen Collection, Computed Tomography, Questionnaire Administration - Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 62 | 2022-04-01 | 2026-08-25 |
| Indo-cyanine Green (ICG) in Paediatric Oncology MIS Indocyanine green - Pediatric Renal Tumor, Metastatic Osteosarcoma | Phase 4 | Completed | Birmingham Women's and Children's NHS Foundation Trust | 20 | 2021-04-30 | 2023-08-14 |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Durvalumab, Oleclumab - Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 75 | 2020-11-26 | 2026-06-22 |
| Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2016-02-04 | 2023-10-26 |
| Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Denosumab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Osteosarcoma, Recurrent Osteosarcoma | Phase 2 | Completed | Children's Oncology Group | 56 | 2015-11-21 | 2024-01-22 |
| Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis - Adult Liposarcoma, Metastatic Liposarcoma | Phase 2 | Completed | Northwestern University | 178 | 2015-03-21 | 2022-06-07 |
| Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma Cabozantinib S-malate, Laboratory Biomarker Analysis - Metastatic Ewing Sarcoma, Metastatic Osteosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2014-12-19 | 2026-08-18 |
| Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma Sm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy - Metastatic Osteosarcoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 | 2013-08-19 | 2019-10-29 |
| Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung pazopanib - Osteosarcoma, Metastatic Osteosarcoma | Phase 2 | Terminated | Emerald Clinical Inc. | 12 | 2013-04-01 | 2021-04-13 |
| Aerosolized Aldesleukin in Treating Patients With Lung Metastases Aerosolized Aldesleukin, Laboratory Biomarker Analysis - Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 70 | 2012-06-28 | 2026-10-15 |
| Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma laboratory biomarker analysis - Localized Osteosarcoma, Metastatic Osteosarcoma | Completed | Children's Oncology Group | 20 | 2011-07-01 | 2015-05-12 | |
| Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma Sorafenib, Everolimus - Metastatic Osteosarcoma, Relapsed Osteosarcoma | Phase 2 | Completed | Italian Sarcoma Group | 38 | 2011-06-01 | 2015-06-17 |
| DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma Laboratory Biomarker Analysis - Localized Osteosarcoma, Metastatic Osteosarcoma | Completed | Children's Oncology Group | 125 | 2010-08-06 | 2022-03-28 | |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas laboratory biomarker analysis - Localized Osteosarcoma, Metastatic Osteosarcoma | Completed | Children's Oncology Group | 34 | 2009-11-01 | 2016-05-19 | |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 178 | 2009-11-01 | 2015-07-30 |
| Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery therapeutic angiotensin-(1-7), laboratory biomarker analysis - Bone Cancer, Chondrosarcoma | Phase 2 | Completed | Wake Forest University Health Sciences | 20 | 2009-10-01 | 2018-07-05 |
| Study of Blood Samples From Patients With Osteosarcoma laboratory biomarker analysis - Localized Osteosarcoma, Metastatic Osteosarcoma | Completed | Children's Oncology Group | 1000 | 2009-01-01 | 2016-05-19 |
Showing 20 of 25. Sign in to see all of them.
Osteosarcoma (25) · Sarcoma (10) · Neuroectodermal Tumors, Primitive, Peripheral (4) · Bone Neoplasms (3) · Chondrosarcoma (3) · Liposarcoma (3) · Desmoplastic Small Round Cell Tumor (2) · Hemangiosarcoma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Rhabdomyosarcoma (2) · Sarcoma, Ewing (2) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Dermatofibrosarcoma (1)
Neoplasms by Histologic Type (25) · Neoplasms, Bone Tissue (25) · Neoplasms, Connective Tissue (25) · Neoplasms, Connective and Soft Tissue (25) · Neoplasms (24) · Sarcoma (15) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neoplasms, Neuroepithelial (4) · Neuroectodermal Tumors, Primitive (4) · Bone Diseases (3) · Musculoskeletal Diseases (3)
Cisplatin (3) · Doxorubicin (3) · Methotrexate (3) · cabozantinib (3) · merphos (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Etoposide (2) · Ifosfamide (2) · Platinum (2) · Radiation (2) · Sorafenib (2) · pazopanib (2) · tanespimycin (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Colony-Stimulating Factors (1)
National Cancer Institute (NCI) (9) · Children's Oncology Group (7) · M.D. Anderson Cancer Center (3) · Birmingham Women's and Children's NHS Foundation Trust (1) · Emerald Clinical Inc. (1) · Italian Sarcoma Group (1) · Northwestern University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Wake Forest University Health Sciences (1)
United States (22) · Canada (6) · Australia (4) · New Zealand (4) · Puerto Rico (4) · France (1) · Italy (1) · Saudi Arabia (1) · Switzerland (1) · United Kingdom (1)
Antoine Italiano (1) · Brian Ladle, MD, PhD (1) · Ching C Lau (1) · David Ebb (1) · Giovanni Grignani, MD (1) · Jeffrey Morgan (1) · Jeremy Rosenblum, MD (1) · John A Livingston, MD (1) · John J Doski (1) · Katherine A Janeway (1) · Mark Agulnik (1) · Mark Ranalli, MD (1) · Massimo Aglietta, MD (1) · Max Pachl (1) · Michael W Bishop (1)
PMID 31401903, PMID 22347360, PMID 23477833, PMID 25421877, PMID 25498219, PMID 27569442, PMID 32078813, PMID 32154021, PMID 34606881, PMID 35075361, PMID 35246418
U10CA180886 (5), U10CA098543 (4), P30CA008748 (2), U01CA069856 (2), 2004 (1), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00100 (1), N01CM62206 (1), P30CA016672 (1), P30CA060553 (1), U01CA062490 (1), U01CA099168 (1)